Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

Trial Profile

Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Fenretinide (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors CerRx
  • Most Recent Events

    • 08 Feb 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
    • 08 Feb 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018 as reported by ClinicalTrials.gov record.
    • 08 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top